The NYHA classification was originally designed as a clinical and not a research tool. [7] It was never meant to serve the purpose of establishing the diagnosis of HF. It was designed purely as a ...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results